Oncology on the move—Artios: Financing Considerations for an Early Biotech

Artios has raised eyebrows, and cash, raising $320 million since its founding in 2016. Led by CEO, Niall Martin, who spearheaded the development of the PARP inhibitor, Lynparza™, along with the scientific guidance of DDR pioneer, Dr. Graeme Smith. In this episode, CFO Abid Ansari details how Artios has been able survive, and thrive in this challenging market environment.